HomeQuestion

Are there specific combinations of DMARDs and/or biologics that you avoid due to elevated infection risk or other safety concerns?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

In light of recent measles outbreaks, have you adjusted your vaccination counseling or preventive strategies for adult immunocompromised patients?

How would you approach management of a patient with ankylosing spondylitis who was doing well on tofacitinib, but experienced a STEMI while on therapy?

In a patient with negative Hep B surface Ag, Hep B surface antibody+, and Hep B core antibody+ serologies, do you initiate antiviral prophylaxis (e.g. entecavir) prior to starting rituximab?

How do you approach management in patients with adult-onset Still’s disease presenting with active polyarthritis (without macrophage activation syndrome) who remain symptomatic despite prednisone 15 mg/day and methotrexate 25 mg/week?

How do you handle medication refills for patients on traditional DMARDs who are lost to follow-up?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.